Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine

Mayo Clinic Proceedings

Volumn 76, Issue 11, 2001, Pages 1093-1101

  Lofland, Jennifer H ^a   Kim, Susan S ^a,g   Batenhorst, Alice S ^b   Johnson, Nelda E ^c,d   Chatterton, Mary Lou ^a,h   Cady, Roger K ^e   Kaniecki, Robert ^f   Nash, David B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Outcomes Research and Design   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Primary Care Network   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g PURDUE PHARMA L P   (United States)

^h MLG Consulting Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MIGRAINE; OUTCOMES RESEARCH; PHARMACY; PRESCRIPTION; QUESTIONNAIRE; TREATMENT OUTCOME; WORK DISABILITY;

EID: 0034758456     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.11.1093     Document Type: Article

References (35)

1. Prevalence of migraine headache in the Unites States: Relation to age, income, race, and other sociodemographic factors
2. Burden of migraine in the United States: Disability and economic costs
3. Health care resource and lost labor costs of migraine headache in the US
4. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks
5. Effectiveness of sumatriptan in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial
6. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine
7. Sumatriptan treatment for migraine in a health maintenance organization: Economic, humanistic, and clinical outcomes
8. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine
9. Subcutaneous sumatriptan for the treatment of migraine: Humanistic, economic, and clinical consequences
10. Improvements in health-related quality of life with sumatriptan treatment for migraine
11. The effects of sumatriptan on migraineurs’ health-related quality of life
12. Quality of life assessment among migraine patients treated with sumatriptan
13. A multinational investigation of the impact of subcutaneous sumatriptan, III: Workplace productivity and non-workplace activity
14. Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial
15. Impact of sumatriptan on clinic utilization and costs of care in migraineurs
16. Sumatriptan use in a large group-model health maintenance organization
17. Cost benefit of sumatriptan to an employer
18. Cost-effectiveness of sumatriptan in a managed care population
19. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine
20. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective
21. The validity and reproducibility of a work productivity and activity impairment instrument
22. Controversies in measuring and valuing indirect costs of productivity foregone in a cost of illness evaluation
23. The economic costs of illness: A replication and update
24. Estimating costs in cost-effectiveness analysis
25. Different approaches to valuing the lost productivity of patients with migraine
26. Working women: Economic and social considerations
27. Aging, natural death, and the compression of morbidity